Magazine

"A Shot In The Arm For Cleveland BioLabs" (Inside Wall Street, Oct. 2, 2006)


In "A shot in the arm for Cleveland BioLabs" (Inside Wall Street, Oct. 2), Curaxins is in phase 2 trials, not phase 3, and has killed human cancer cells transplanted into animals, not primates. And Cleveland Clinic will provide the equivalent of $5 million in research and infrastructure.


Cash Is for Losers
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus